Evidence map›Paper›PMID 34355791›Full record

ArticleThe Laryngoscope2022

Adjuvant Therapy and Prognosticators of Survival in Head and Neck Mucosal Melanoma.

Arash Abiri, Tyler M Yasaka, Brandon M Lehrich, Khodayar Goshtasbi, Peter Papagiannopoulos, Bobby A Tajudeen, Maie A St John, Jeremy P Harris, Edward C Kuan

Open access · greenAbstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in The Laryngoscope, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it

0cells of the map it votes in

9citing papers in PubMed

2.4field-weighted citation impact, top 8% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

Head and Neck Mucosal Melanoma in the Era of Immunotherapy: A National Cancer Database Review.Head & neck · 2026
Article
Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial.BMJ open · 2026
Article
Sinonasal Mucosal Melanoma Survival Outcomes, Recurrence Patterns, and Prognostic Factors: A Systematic Literature Review and Meta-analysis of Publications after 2000.Journal of neurological surgery. Part B, Skull base · 2025
Article
Surgical resection and overall survival in cT4b sinonasal non-squamous cell carcinoma.Laryngoscope investigative otolaryngology · 2024
Article
Mutational landscape and predictors of survival in head and neck mucosal melanoma.International forum of allergy & rhinology · 2024
Article
Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mTOR pathway in mucosal melanoma fitness.Journal of translational medicine · 2024
Article
Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes.Frontiers in immunology · 2024
Review
Treatment outcomes of the patient with sinonasal mucosal melanoma: the role of endoscopic resection and postoperative radiotherapy.International journal of clinical oncology · 2023
Article
Combination of Postoperative Adjuvant Chemoradiotherapy and Immune Checkpoint Inhibitors Significantly Prolongs Recurrence-Free Survival in Sinonasal Mucosal Melanoma.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Arash AbiriDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.ORCID 0000-0003-2656-1060

Tyler M YasakaDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.ORCID 0000-0002-8482-0369

Brandon M LehrichDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.ORCID 0000-0003-1003-5605

Khodayar GoshtasbiDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.

Peter PapagiannopoulosDepartment of Otolaryngology-Head and Neck Surgery, Rush University Medical Center, Chicago, Illinois, U.S.A.

Bobby A TajudeenDepartment of Otolaryngology-Head and Neck Surgery, Rush University Medical Center, Chicago, Illinois, U.S.A.

Maie A St JohnDepartment of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, California, U.S.A.ORCID 0000-0001-7068-9534

Jeremy P HarrisDepartment of Radiation Oncology, University of California, Irvine, California, U.S.A.

Edward C KuanDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.ORCID 0000-0003-3475-0718

University of California, Irvine · USRush University Medical Center · USUniversity of California, Los Angeles · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christine Hui · 1994 to 2026

$57.9M

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008620 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI GOLDIN, ALAN L · 1999 to 2023

$8.1M

NCI NIH HHS P30 CA062203NIGMS NIH HHS T32 GM008620

6 · The paper itself

Abstract

objectives/hypothesisTo identify prognosticators and determine the efficacies of surgery with adjuvant radiotherapy (SR) and surgery with immunotherapy (SI) of head and neck mucosal melanoma (HNMM). STUDY

designRetrospective database study.

methodsThe 2004 to 2017 National Cancer Database was queried for HNMM patients. Cox proportional hazards and Kaplan-Meier analyses evaluated prognosticators of mortality and survival benefits conferred by SR, SI, or surgery with adjuvant radiotherapy and immunotherapy (SRI). Logistic regression identified predictors of adjuvant radiotherapy or immunotherapy use.

resultsOverall, 1,910 cases (845 surgery, 802 SR, 51 SI, 101 SRI) were analyzed, with 50.3% females and an average age of 68.6 ± 13.8 years. SI was associated with greater overall survival (OS) than surgery (hazard ratio [HR] 0.672; P = .036). SI (HR 0.425; P = .024) and SRI (HR 0.594; P = .045) were associated with superior OS than SR. Older age (HR 1.607; P < .001), female sex (HR 0.757; P = .006), paranasal sinus localization (HR 1.648; P < .001), T4 classification (HR 1.443; P < .001), N1 classification (HR 2.310; P < .001), M1 classification (HR 3.357; P < .001), and positive surgical margins (HR 1.454; P < .001) were survival prognosticators. Adjuvant radiotherapy use was negatively correlated with older age, oral cavity localization, and M0 or T3 tumors (all P < .05). Adjuvant immunotherapy use was positively correlated with younger age and M1 tumors (all P < .05).

conclusionsAlthough SR did not confer survival benefits in HNMM patients, SI and SRI yielded greater OS than surgery alone. SRI was associated with superior survival outcomes than SR. Certain demographic and clinical factors were associated with increased mortality risk. Patient age and certain tumor characteristics were predictors of adjuvant radiotherapy or immunotherapy use. LEVEL OF EVIDENCE: 4 Laryngoscope, 132:584-592, 2022.

Indexed as

AgedChemotherapy, AdjuvantFemaleHead and Neck NeoplasmsHumansImmunotherapyKaplan-Meier EstimateLogistic ModelsMaleMelanomaMiddle AgedPrognosisProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival Analysishead and neckimmunotherapyMucosal melanomaradiation therapysurvival outcomes

Identifiers

PMID34355791

DOI10.1002/lary.29807

PMCPMC12685567

OpenAlexW3188527260

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.